稳健医疗(300888) - 2023 Q1 - 季度财报

Revenue and Profit Performance - Revenue for the reporting period was RMB 2,352,114,690.56, a year-on-year increase of 1.28%[4] - Net profit attributable to shareholders of the listed company was RMB 376,938,135.34, a year-on-year increase of 5.56%[4] - Revenue for Q1 2023 reached 2.352 billion yuan, a year-on-year increase of 1.28%[17] - Net profit attributable to shareholders was 377 million yuan, up 5.56% year-on-year[17] - Total revenue for Q1 2023 was 2,352,114,690.56 RMB, a slight increase from 2,322,337,445.27 RMB in the same period last year[23] - Net profit attributable to the parent company was 376,938,135.34 RMB, up from 357,101,020.81 RMB in the previous year[24] - Operating profit increased to 452,706,688.99 RMB from 424,041,383.48 RMB in the same period last year[24] - Comprehensive income for the period totaled RMB 387,215,004.85, with RMB 376,520,909.14 attributable to owners of the parent company[25] - Basic and diluted earnings per share were RMB 0.89, compared to RMB 0.84 in the same period last year[25] Cash Flow and Financial Activities - Net cash flow from operating activities was RMB -223,247,317.38, a year-on-year decrease of 156.20%, mainly due to reduced advance receipts and increased tax payments[5] - Total cash from operating activities increased by 66.42% to 189.31 million yuan[14] - Net cash flow from operating activities was negative RMB 223,247,317.38, compared to positive RMB 397,234,802.12 in the same period last year[27] - Cash received from sales of goods and services was RMB 2,128,547,397.71, a decrease from RMB 2,472,159,804.38 in the previous year[26] - Cash received from investments was RMB 1,414,889,285.00, down from RMB 1,644,215,024.46 in the previous year[27] - Net cash flow from investing activities was negative RMB 178,675,407.47, an improvement from negative RMB 479,044,186.87 in the same period last year[27] - Cash received from financing activities was RMB 683,000,000.00, significantly higher than RMB 100,000,000.00 in the previous year[28] - Net cash flow from financing activities was positive RMB 262,960,743.92, compared to negative RMB 189,666,448.38 in the same period last year[28] - The company's cash and cash equivalents balance at the end of the period was RMB 4,228,193,978.89, down from RMB 4,370,821,958.17 at the beginning of the period[28] Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,029,711,042.27, a decrease of 1.82% compared to the end of the previous year[5] - Total assets decreased to 18,029,711,042.27 RMB from 18,363,337,775.74 RMB at the end of the previous quarter[20][22] - Total liabilities decreased to 5,433,948,305.94 RMB from 6,165,408,250.94 RMB at the end of the previous quarter[21][22] - Inventory decreased to 1,457,644,395.50 RMB from 1,558,923,573.37 RMB at the end of the previous quarter[20] - Total equity increased to 12,595,762,736.33 RMB from 12,197,929,524.80 RMB at the end of the previous quarter[22] - Short-term borrowings increased to 2,423,356,166.66 RMB from 2,295,218,930.85 RMB at the end of the previous quarter[21] - Fixed assets increased to 2,373,863,413.45 RMB from 2,312,982,598.88 RMB at the end of the previous quarter[20] Non-Recurring Items and Other Income - Non-recurring gains and losses amounted to RMB 67,103,259.25, including government subsidies of RMB 19,881,777.62 and gains from financial assets of RMB 57,736,019.94[7] - Other income increased by 49.66% to RMB 19,878,777.62, mainly due to increased government subsidies[11] - Fair value change income increased by 178.75% to RMB 46,133,616.18, mainly due to gains from structured deposits[12] Taxes and Expenses - Taxes paid increased by 200.53% to RMB 290,271,355.72, mainly due to higher corporate income tax and VAT payments[13] - R&D expenses increased to 111,178,989.49 RMB from 94,410,776.54 RMB in the same period last year[23] - Dividend and interest payments increased by 1178.84% to 5.11 million yuan[14] Borrowings and Loans - Long-term loans increased to RMB 200,000,000.00, as the company secured additional long-term bank loans[10] - Borrowings received surged 583% to 683 million yuan[14] Revenue by Product Category - Healthcare consumables revenue decreased by 3.99% to 1.364 billion yuan, with infection protection products revenue dropping 38.21% to 617 million yuan[17] - Regular healthcare consumables revenue surged 76.9% to 747 million yuan[17] - Healthy lifestyle consumer goods revenue grew 10.53% to 969 million yuan, with non-woven consumer goods up 4.3% to 501 million yuan and woven consumer goods up 18.1% to 468 million yuan[17] - Domestic hospital channel revenue fell 38.8% to 429 million yuan due to decreased demand for infection protection products[17] Contract Liabilities and Shareholder Information - Contract liabilities decreased by 58.20% to RMB 236,924,762.49, mainly due to the resumption of normal credit policies for infection protection products[10] - The top shareholder, Wenjian Group Limited, holds 68.10% of the shares, totaling 290.44 million shares[15] Miscellaneous - The first quarter report was unaudited[29]